Products
Online Inquiry
Lenvatinib
Cat. No.:
OB0125LY-080
Appearance:
Solid
Purity:
99.8%
Identity:
Confirmed by NMR and HPLC.
Size:
Add to basket
Product Overview
Description:
Lenvatinib is a multi-targeted tyrosine kinase inhibitor that inhibits a variety of signaling pathways associated with cell growth and angiogenesis.
Synonym:
417716-92-8; E7080; 4-(3-Chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide; 4-[3-Chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide; 4-[3-Chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide; 4-[3-Chloro-4-[[ (cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide; 4-[3-Chloro-4-[[ (cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide
CAS No.:
417716-92-8
Compound CID:
9823820
Formula:
C21H19ClN4O4
Formula Weight:
426.85
Specification
Targets & IC50:
PDGFRβ: 39 nM; VEGFR1/FLT1: 22 nM; FGFR1: 46 nM; VEGFR2/KDR: 4.0 nM; VEGFR3/FLT4: 5.2 nM
Relative Density:
1.46 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Lenvatinib has strong anti-tumor activity and can be used for anti-tumor drug development.
Library Information
Targets:
VEGFR; FGFR; c-Kit; PDGFR; c-RET
Receptors:
c-Kit; FGFR; FGFR1; PDGFR; PDGFRβ; RET; VEGFR; VEGFR1/FLT1; VEGFR2/KDR; VEGFR3/FLT4
Pathways:
Apoptosis; Angiogenesis; Tyrosine kinase/adaptors
Plate Number:
AOCL-10
Plate Location:
h10
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
15 mg/mL; 35.14 mM
Water Max Solubility:
1 mg/mL
Saline Max Solubility:
1.9 mg/mL; 4.45 mM
ALogP:
2.832
HBA_Count:
5
HBD_Count:
3
Rotatable Bond:
6
